KR102111792B1 - 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 - Google Patents

에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 Download PDF

Info

Publication number
KR102111792B1
KR102111792B1 KR1020187030877A KR20187030877A KR102111792B1 KR 102111792 B1 KR102111792 B1 KR 102111792B1 KR 1020187030877 A KR1020187030877 A KR 1020187030877A KR 20187030877 A KR20187030877 A KR 20187030877A KR 102111792 B1 KR102111792 B1 KR 102111792B1
Authority
KR
South Korea
Prior art keywords
group
umol
mmol
compound
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187030877A
Other languages
English (en)
Korean (ko)
Other versions
KR20180128456A (ko
Inventor
젠위 루
찰스 제트. 딩
리홍 후
후이준 허
슈후이 첸
지아창 동
티에-린 왕
Original Assignee
뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드
산둥 뤄신 파마슈티컬 그룹 스탁 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드, 산둥 뤄신 파마슈티컬 그룹 스탁 컴퍼니 리미티드 filed Critical 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드
Publication of KR20180128456A publication Critical patent/KR20180128456A/ko
Application granted granted Critical
Publication of KR102111792B1 publication Critical patent/KR102111792B1/ko
Assigned to 뤄신 헬스케어 사이언스 앤드 테크놀로지 디벨롭먼트 (베이징) 리미티드 reassignment 뤄신 헬스케어 사이언스 앤드 테크놀로지 디벨롭먼트 (베이징) 리미티드 권리의 전부이전등록 Assignors: 뤄신 파마슈티컬 (상하이) 컴퍼니 리미티드, 산둥 뤄신 파마슈티컬 그룹 스탁 컴퍼니 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
KR1020187030877A 2016-03-25 2017-03-24 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 Active KR102111792B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610180518.7 2016-03-25
CN201610867918.5 2016-09-29
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (2)

Publication Number Publication Date
KR20180128456A KR20180128456A (ko) 2018-12-03
KR102111792B1 true KR102111792B1 (ko) 2020-05-18

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187030877A Active KR102111792B1 (ko) 2016-03-25 2017-03-24 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물

Country Status (11)

Country Link
US (1) US10519143B2 (cg-RX-API-DMAC10.html)
EP (1) EP3434668B1 (cg-RX-API-DMAC10.html)
JP (1) JP6790222B2 (cg-RX-API-DMAC10.html)
KR (1) KR102111792B1 (cg-RX-API-DMAC10.html)
CN (1) CN108884035B (cg-RX-API-DMAC10.html)
AU (1) AU2017239348B2 (cg-RX-API-DMAC10.html)
CA (1) CA3018801C (cg-RX-API-DMAC10.html)
ES (1) ES2821407T3 (cg-RX-API-DMAC10.html)
RU (1) RU2722441C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201808363TA (cg-RX-API-DMAC10.html)
WO (1) WO2017162206A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032627B (zh) 2017-09-25 2023-10-20 罗欣健康科技发展(北京)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3889136B1 (en) * 2018-11-28 2024-12-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
AU2019400398B2 (en) * 2018-12-17 2024-10-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Estrogen receptor antagonist
CN116891461B (zh) * 2022-03-30 2026-05-15 罗欣药业(上海)有限公司 一种serd中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9499538B2 (en) * 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MA39740A (fr) * 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Also Published As

Publication number Publication date
CA3018801A1 (en) 2017-09-28
RU2018135203A3 (cg-RX-API-DMAC10.html) 2020-04-27
RU2722441C2 (ru) 2020-06-01
CN108884035A (zh) 2018-11-23
US20190106414A1 (en) 2019-04-11
ES2821407T3 (es) 2021-04-26
SG11201808363TA (en) 2018-10-30
US10519143B2 (en) 2019-12-31
EP3434668B1 (en) 2020-08-26
RU2018135203A (ru) 2020-04-27
EP3434668A4 (en) 2019-08-14
ES2821407T8 (es) 2022-02-02
CN108884035B (zh) 2020-03-13
WO2017162206A1 (zh) 2017-09-28
EP3434668A1 (en) 2019-01-30
AU2017239348B2 (en) 2020-03-12
JP2019512550A (ja) 2019-05-16
JP6790222B2 (ja) 2020-11-25
CA3018801C (en) 2020-06-23
KR20180128456A (ko) 2018-12-03
HK1256936A1 (zh) 2019-10-04
AU2017239348A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
JP7290638B2 (ja) Wee1阻害剤としての大環状化合物及びその使用
JP6717457B2 (ja) Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
JP2022518591A (ja) 複素環式化合物であるベンゾピリドンおよびその使用
IL286352B2 (en) Novel small molecule inhibitors of TEAD transcription factors
JP7237010B2 (ja) Hdac6選択的阻害剤およびその製造方法と使用
KR102244216B1 (ko) 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도
JP6790222B2 (ja) エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
CN116867778A (zh) 苯并七元环类双功能化合物及其应用
KR102254660B1 (ko) A2a수용체 억제제로서의 축합 고리 유도체
CN103910643B (zh) 一种抗癌活性甲酮衍生物、合成方法及其用途
JP6951418B2 (ja) 抗hcmvウイルス化合物
CN116438177B (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
AU2023246242A1 (en) Tetrahydronaphthalene derivative
JP7716980B2 (ja) エストロゲン受容体拮抗剤
CN100502846C (zh) 3,4,5-三取代的苯丙烯类衍生物及其制备方法和用途
WO2019120198A1 (zh) 一类喹啉衍生物
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
HK1256936B (en) Substituted-indole compounds as estrogen receptor down-regulators
JPH07500571A (ja) Pcpレセプター・リガンドおよびその用途
HK40080061B (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
HK40009263B (en) Azetidine derivative
JPS61158951A (ja) 生物体殺滅活性を有する多環状化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6